28 March 2024 - Another slim agenda; one cancer medicine. ...
1 April 2024 - Approval of first in class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase ...
1 April 2024 - Eisai and Biogen announced today that Eisai submitted to the US FDA a supplemental biologics license ...
1 April 2024 - Target action date set for 19 November 2024. ...
1 April 2024 - The April 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
1 April 2024 - The April 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
29 March 2024 - Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be ...
28 March 2024 - Indication includes children ages 6 years and older and weighing at least 30 kg. ...
28 March 2024 - First marketing authorisation submission for sepiapterin with additional global submissions to follow in 2024. ...
28 March 2024 - D&D Pharmatech said Thursday that DD01, an injectable treatment for metabolic-associated steatohepatitis (MASH) being developed by ...
27 March 2024 - Otsuka Pharmaceutical announces that its subsidiary Otsuka Pharmaceutical Europe and Lundbeck announced that the European Commission ...
28 March 2024 - Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing ...
26 March 2024 - PDUFA date set for 24 September 2024. ...
28 March 2024 - Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable non-small cell lung ...
27 March 2024 - Once daily oral HIF-PH inhibitor activates physiologic response to manage anaemia. ...